DOSE CONTEXT / RESEARCH FIGURES
How BPC-157 Doses Are Expressed in the Research
The doses, routes, and pharmacokinetics reported in the BPC-157 literature — read exactly as the studies express them. These are animal-model and pilot figures, not human dosing guidance.
How BPC-157 Doses Are Expressed in the Research
BPC-157 dosage in the published literature is reported per body weight in animals, and the figures are small. Rodent studies commonly express doses around 10 micrograms per kilogram and 10 nanograms per kilogram, and some tendon work has gone as low as 10 picograms [1]. The foundational gastric-ulcer cytoprotection studies used 400 ng/kg and 800 ng/kg in rats, with the higher doses producing the 45.7-65.6% inhibition of ulcer formation [4].
These are animal-model figures. They describe what was administered to rats and dogs in controlled studies — not a recommended human dose, and not a protocol. This page reports the research record; it does not tell anyone what to take. Human exposure, where it exists at all, is described below and is limited to a few pilot subjects.
BPC-157 Half-Life in Animal Pharmacokinetics
The BPC-157 half-life is short in the only formal pharmacokinetic characterization available. A 2022 PK/ADME study in rats and beagle dogs reported linear pharmacokinetics, an elimination half-life under 30 minutes, and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [2]. Intramuscular bioavailability was modest — roughly 14-19% in rats and 45-51% in dogs — with excretion via urine and bile [2].
A half-life under 30 minutes is brief, and it shapes how the peptide has been dosed in animal studies: typically once daily across a multi-day healing course rather than as a single intervention. Human pharmacokinetics have not been characterized [2]. The animal PK is precise; the human PK is simply absent.
BPC-157 Injection Routes Used in Studies
BPC-157 injection in research has used several routes. In rodent work, the intraperitoneal route is most common, with intramuscular, local or intra-lesional, and intragastric or peroral routes also studied [1][4]. The formal pharmacokinetic study used intravenous and intramuscular routes [2].
Human pilot exposures used routes matched to the condition under study: intravenous infusion in the 2025 two-adult safety pilot [7], intravesical (into the bladder) in the 2024 interstitial-cystitis pilot [12], and intra-articular (into the joint) in the 2021 knee-pain case series [6]. Each route in the human pilots was a single defined exposure in a small, uncontrolled study — not an established administration schedule.
One reason route matters so much for this peptide is the gastric-stability claim. Because BPC-157 is reported to be stable in gastric juice, oral and intragastric routes have been studied where most peptides would simply be digested [5]. But the only formal pharmacokinetic characterization used intravenous and intramuscular routes, so the systemic profile of an oral dose in humans is uncharacterized [2]. Route, in other words, is not a free parameter in the BPC-157 literature — the evidence behind each route differs sharply, and the well-quantified pharmacokinetics belong to the injected routes.
How long should I stay on BPC-157?
There is no validated human protocol. Animal studies use defined dosing courses — typically once-daily dosing over a healing window of days to weeks — but those are experimental designs, not human guidance. A 2025 review urges treating BPC-157 as investigational [8], and no controlled human trial has established a duration. This page reports how the studies were run; it does not prescribe a course for anyone.
The Human-Pilot Doses, for Completeness
Human BPC-157 doses on record are sparse and belong to pilot studies, not dosing guidelines. The 2025 intravenous safety pilot used 10 mg, then 20 mg, by infusion in two healthy adults [7]. The 2024 interstitial-cystitis pilot used a single 10 mg intravesical dose during cystoscopy [12]. The 2021 knee-pain case series used intra-articular injection, with the dose not stated [6]. These figures are reported here only to describe the human exposures that have actually been studied; they are not recommendations, and the studies themselves were small and uncontrolled [8].
One consequence of the animal-to-human gap is worth stating plainly. The rodent figures are expressed per kilogram in micrograms or nanograms [1]; the human pilots used fixed milligram amounts [7]. Those are not interchangeable, and no published work bridges them into a validated human dose. Storage and reconstitution practices sometimes described in research handling are likewise research-context, not clinical procedures [5].